Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecan

Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecan - Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044278

Enrollment

Registered

2021-07-31

Start date

2021-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

salivary gland carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects treated with trastuzumab deruxtecan in Investigator Initiated Study of trastuzumab deruxtecan for salivary gland cancer

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Immune cell profile analysis Genome mutation analysis mRNA expression analysis Proteomics analysis Multicolor IHC analysis AI pathological analysis Blood cfDNA analysis Blood cfRNA / miRNA analysis, etc.	—

Countries

Japan

Contacts

Public ContactYudai Watanabe

Hokkaido University Hospital Clinical Research and Medical Innovation Center

tr_ds-8201a_jimu@pop.med.hokudai.ac.jp0117067735

Outcome results